Dainippon Sumitomo Pharma Biomedical To Market Serum Free STK2
This article was originally published in PharmAsia News
Dainippon Sumitomo Pharma's biopharma subsidiary, Hiroshima-based DS Pharma Biomedical will market STK2, a human mesenchymal stem cell made by serum-free culture media on May 12. The company obtained the serum-free media technology from Twocell, a Japanese regenerative medicine venture company also based in Hiroshima. Currently, fetal bovine serum or human serum is needed to culture human mesenchymal stem cells. The company comments that the product will contribute greatly to the regenerative medicine area. (Click here for more - Japanese language)
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.